Zentalis reports FY2025 results; cash $245.9M, DENALI Part 2 topline due year-end 2026

Zentalis Pharmaceuticals, Inc.

Cash, equivalents and marketable securities $245.9M as of Dec 31, 2025; projected runway into late 2027.
R&D expenses $107.3M (down 36% YoY); G&A expenses $37.7M (down 57% YoY).
DENALI Part 2a enrollment completed; monotherapy dose confirmation expected 1H 2026.
DENALI Part 2 topline readout on track for year-end 2026; potential to support accelerated approval.
ASPENOVA Phase 3 confirmatory trial (azenosertib vs chemo in Cyclin E1+ PROC) to initiate 1H 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 26, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.